[Scientific Reports] Researchers investigated the role of LIMK2, a component of the Rho/ROCK/LIMK/cofilin pathway, in cell differentiation and apoptosis in response to mechanical stimulation and proliferation in human dermal fibroblasts.
[FEBS Journal] Investigators provide an overview of the latest findings describing the roles of major bioactive fragments from collagens I, IV, VI, and XVIII in various physiological and pathological contexts affecting heart, lung, adipose, and even brain tissues.
[Apoptosis] The authors offer a systematic summary of the roles played by major cell adhesion molecules families—namely, the immunoglobulin superfamily, cadherins, and integrins—in the regulation of ferroptosis.
[FibroBiologics, Inc.] FibroBiologics, Inc. announced that the Canadian Intellectual Property Office has issued Canadian Patent No. 3118732, titled “Treatment of Cachexia Using Fibroblast Cells and Products Thereof.”
[Tissue Engineering and Regenerative Medicine] Researchers investigated endothelial cells from the stromal vascular fraction of human subcutaneous white adipose tissue in 2D culture and 3D bioengineered skin models to better define their specific subtypes.
[Journal of Neurochemistry] Scientists investigated whether ethanol-induced effects on endothelial cells involve epigenetic reprogramming, specifically through alterations in DNA methylation profiles.
[Washington University] A cell-based immunotherapy developed by Washington University researchers has been granted Breakthrough Therapy designation by the US FDA.
[University of Colorado (CU) Anschutz] The University of Colorado Anschutz Gates Institute has received Investigational New Drug clearance from the US FDA, marking the first CAR-T cell therapy authorized for clinical testing that was developed entirely on the CU Anschutz campus.
[AvenCell Therapeutics, Inc.] AvenCell Therapeutics, Inc. announced that it has dosed the first patient in the Phase I QUADvance study with AVC-203 for the treatment of relapsed/refractory B cell malignancies.